« Si c’est recommandé c’est pas obligatoire, c’est inutile ». Analyse psychosociale des freins à la vaccination antigrippale chez les IDE(s) : vers une reconstruction sociale de la recommandation

International audienc

« Si c’est recommandé c’est pas obligatoire, c’est inutile ». Analyse psychosociale des freins à la vaccination antigrippale chez les IDE(s) : vers une reconstruction sociale de la recommandation

International audienc

Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial)

Abstract: Retrospective studies reported that preoperative oxaliplatin-based chemotherapy increased pathological response (PR) in patients resected for colorectal liver metastases (CRLM). This multicenter prospective randomized (1/1) phase II trial evaluated PR on resected CRLM after preoperative mFOLFOX6 (arm A) or FOLFIRI (arm B) + bevacizumab. The primary endpoint was the major pathological response rate (MPRR), defined as the percentage of patients presenting CRLMs with mean tumor regression grade (TRG) < 3. Secondary endpoints included safety, progression-free survival (PFS) and overall survival (OS). Out of 65 patients, 57 patients (28 and 29 in arm A/B) were resected for CRLM (one patient with lung metastases). Clinical and treatment characteristics were similar in both arms. One-month postoperative complications were 39.3%/31.0% in arm A/B (p = 0.585). MPRR and complete PR were 32.1%/20.7% (p = 0.379

Randomized phase II studies comparing pathological responses observed on colorectal cancer metastases resected after preoperative treatment combining bevacizumab or cetuximab with FOLFOX or FOLFIRI.

Background: Even if the use of targeted therapies combined with chemotherapy has demonstrated increase response rate and survival benefit in non resectable metastatic colorectal cancer (mCRC), the administration of these combinations in frontline resectable disease is source of debate and optimal association is still unclear. Based on a retrospective analysis, we previously reported thatthe chemotherapy partner combined with VEGF or EGFR inhibitors influenced pathological responses (pR) on the resected colorectal cancer metastases (CRCM) with a significant advantage for oxaliplatin with anti-VEGF or irinotecan with anti-EGFR combinations. We aimed to design 2 parallel studies (BEV-ONCO, CET-ONCO) to prospectively precise optimal combination between oxaliplatin and irinotecan with bevacizumab or cetuximab before CRCM resection. Methods: The 2 studies are open label randomized multi-centric trials and concern mCRC patients with resectable disease in whom a preoperative treatment is considered. The primary objective is to assess the CRCM pR rate according the Tumor Regression Grade classification (Rubbia-Brandt) after allocated preoperative treatment (bevacizumab combined with FOLFOX vs. FOLFIRI without consideration of RAS/BRAF for BEV-ONCO trial (EUDRACT 2012-005376-34) and cetuximab associated with FOLFOX or FOLFIRI only for RAS/BRAF wild type tumor for CET-ONCO trial (EUDRACT 2012-005249-19)). According investigator’s choice, patient will received 3 to 6 treatment cycles before CRCM resection. Patient’s survival, safety, surgical complications and treatment associated liver-toxicity are secondary end-points. Up to 60 patients (30 per treatment group) will be randomised in each study (power: 80%, type I error of 5% to detect a difference in proportion of pR rate between FOLFOX or FOLFIRI association of 0.40). Formal comparison will not be done across studies. Translational research projects are ongoing (CRCM immune response, tumour specific genetic rearrangements as new specific biomarkers). Clinical trial information: NCT01858649 (BEV-ONCO); NCT01858662 (CET-ONCO). Clinical trial information: NCT01858649 (BEVONCO) NCT01858662 (CETONCO)

Faciès mobiliers et entités ethno-politiques à la Tène finale : réflexions préliminaires sur l’installation des Tigurins en Suisse occidentale

International audienceThe aims and approaches of a work group composed of researchers studying the second and first centuries BC in Western Switzerland (GR II-I) are outlined, presenting the methods deployed to study, and the preliminary results of an examination of the sudden break in both the settlement pattern and material culture facies of western Switzerland at the turn of the first century BC (LT D1b-D2a). A variety of approaches, numismatic and based on pottery studies, allows an initial objective definition of these changes and the hypothesis of a link between these material culture changes and the settlement on the Tigurini in the west of the Swiss plateau in the wake of the war with the Cimbri.L’article présente les objectifs et les activités d’un nouveau groupe de recherche travaillant sur les IIe et Ier siècles av. n. è. sur le Plateau suisse (GR II-I) et se concentre sur les méthodes et les premiers résultats d’une enquête consacrée à la rupture observée aussi bien dans l’occupation du territoire que dans les faciès de mobilier en Suisse occidentale au début du Ier siècle av. n. è. (transition LT D1b-LT D2a). Différents axes de comparaisons numismatiques et céramologiques permettront une première caractérisation objective de ces phénomènes et de tester l’hypothèse d’un lien entre ces derniers et l’installation des Helvètes Tigurins dans l’ouest du Plateau après les guerres cimbriques

Bulletin Bibliographique

À tous les lecteurs et collaborateurs du Bulletin Bibliographique des ASSR Pour la première fois cette année nous mettons en ligne les comptes-rendus sur note site Revues.org au rythme semestriel (juin / décembre) qui est celui des échéances du Bulletin Bibliographique. La totalité des recensions de l'année 2009 sera publiée dans notre numéro 148 (octobre-décembre)